<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590122</url>
  </required_header>
  <id_info>
    <org_study_id>H-19596</org_study_id>
    <nct_id>NCT00590122</nct_id>
  </id_info>
  <brief_title>Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study</brief_title>
  <official_title>COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out if a single dose of Parcopa®, a form of levodopa that dissolves in your mouth,&#xD;
      works faster than regular oral levodopa which is swallowed, in fluctuating PD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to on</measure>
    <time_frame>first dose of day for each arm</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parcopa at equivalent dosage to subjects surrent stable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carbidopa-levodopa at subjects current stable dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parcopa</intervention_name>
    <description>at subjects current stable dose of comparator</description>
    <arm_group_label>b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbidopa-levodopa</intervention_name>
    <description>at subjects current stable dose</description>
    <arm_group_label>a</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between the age of 31 and 80 -Diagnosis of idiopathic Parkinson's&#xD;
             disease for at least three years duration&#xD;
&#xD;
          -  Patients requiring levodopa for their PD&#xD;
&#xD;
          -  Good subjective response to levodopa&#xD;
&#xD;
          -  Fluctuating symptoms defined by wearing off phenomenon, any dyskinesia, and/or dose&#xD;
             failures&#xD;
&#xD;
          -  A UPDRS -off- motor score of at least 25&#xD;
&#xD;
          -  Subjects willing to give informed consent&#xD;
&#xD;
          -  Subjects who are able and willing to comply with study procedures&#xD;
&#xD;
          -  If female of child-bearing potential, will use one of the approved birth control&#xD;
             measures:&#xD;
&#xD;
               1. Hormonal contraceptives&#xD;
&#xD;
               2. Spermicidal and barrier&#xD;
&#xD;
               3. Intrauterine device&#xD;
&#xD;
               4. Partner sterility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with evidence of significant dementia&#xD;
&#xD;
          -  Subjects with significant oral lesions&#xD;
&#xD;
          -  History of unstable cardiac disease including angina or congestive heart failure&#xD;
             within 3 months prior to study entry&#xD;
&#xD;
          -  History of clinically significant renal disease including renal insufficiency of&#xD;
             sufficient degree to require adjunctive treatment or dietary restrictions&#xD;
&#xD;
          -  History of clinically significant hepatic disease, including previously documented&#xD;
             cirrhosis or hepatic insufficiency or jaundice within 3 months prior to study entry.&#xD;
&#xD;
          -  Subjects with poor response to levodopa&#xD;
&#xD;
          -  Women who are pregnant, breast-feeding, or planning to become pregnant during this&#xD;
             study are excluded from participation due to unknown effects of the study drug on the&#xD;
             fetus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Ondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PDCMDC 6550 Fannin, Suite 1801</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>March 12, 2009</last_update_submitted>
  <last_update_submitted_qc>March 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>William G. Ondo, MD</name_title>
    <organization>Baylor College of Medicine</organization>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>time to &quot;on&quot;</keyword>
  <keyword>delayed on</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 22, 2017</submitted>
    <returned>September 19, 2017</returned>
    <submitted>October 2, 2017</submitted>
    <returned>October 31, 2017</returned>
    <submitted>October 31, 2017</submitted>
    <returned>December 4, 2017</returned>
    <submitted>April 5, 2018</submitted>
    <returned>May 7, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

